% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Raut:289128,
author = {J. Raut$^*$ and M. Bhardwaj$^*$ and B. Schöttker$^*$ and
B. Holleczek and P. Schrotz-King$^*$ and H. Brenner$^*$},
title = {{C}ancer-specific risk prediction with a serum micro{RNA}
signature.},
journal = {Cancer science},
volume = {115},
number = {6},
issn = {1344-6428},
address = {Tokyo},
publisher = {Assoc.},
reportid = {DKFZ-2024-00595},
pages = {2049-2058},
year = {2024},
note = {#EA:C070#LA:C070#LA:C120# / 2024 Jun;115(6):2049-2058},
abstract = {We recently derived and validated a serum-based microRNA
risk score (miR-score) that predicted colorectal cancer
(CRC) occurrence with very high accuracy within 14 years of
follow-up in a population-based cohort study from Germany
(ESTHER cohort). Here, we aimed to evaluate associations of
the CRC-specific miR-score with the risk of developing other
common cancers, including female breast cancer (BC), lung
cancer (LC), and prostate cancer (PC), in the ESTHER cohort.
MicroRNAs (miRNAs) were profiled by quantitative real-time
PCR in serum samples collected at baseline from randomly
selected incident cases of BC (n = 90), LC (n = 88), and PC
(n = 93) and participants without diagnosis of CRC, LC, BC,
or PC (controls, n = 181) until the end of the 17-year
follow-up. Multivariate logistic regression models were used
to evaluate the associations of the miR-score with BC, LC,
and PC incidence. The miR-score showed strong inverse
associations with BC and LC incidence [odds ratio per 1
standard deviation increase: 0.60 $(95\%$ confidence
interval [CI] 0.43-0.82), p = 0.0017, and 0.64 $(95\%$ CI
0.48-0.84),p = 0.0015, respectively]. Associations with PC
were not statistically significant but pointed in the
positive direction. Our study highlights the potential of
serum-based miRNA biomarkers for cancer-specific risk
prediction. Further large cohort studies aiming to
investigate, validate, and optimize the use of circulating
miRNA signatures for cancer risk assessment are warranted.},
keywords = {breast cancer (Other) / circulating miRNA (Other) /
colorectal cancer (Other) / lung cancer (Other) / prostate
cancer (Other) / risk prediction (Other) / risk
stratification (Other)},
cin = {C070 / C120 / HD01},
ddc = {610},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
I:(DE-He78)HD01-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38523358},
doi = {10.1111/cas.16135},
url = {https://inrepo02.dkfz.de/record/289128},
}